Literature DB >> 16669842

The implications of a growing evidence base for drug use in elderly patients Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients.

A A Mangoni1, S H D Jackson.   

Abstract

Traditionally, angiotensin converting enzyme (ACE) inhibitors have been used for the management of patients with congestive cardiac failure. Studies performed over the last decade have demonstrated that (1) angiotensin receptor blockers (ARBs) are as effective as ACE inhibitors in reducing morbidity and mortality in cardiac failure; and (2) inhibition of the renin-angiotensin system provides beneficial effects in patients at high cardiovascular risk without cardiac failure. This review focuses on the applicability of the results of the main trials with ACE inhibitors and ARBs to the elderly population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16669842      PMCID: PMC1885051          DOI: 10.1111/j.1365-2125.2006.02610.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  35 in total

1.  Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators.

Authors:  J G Cleland; M Tendera; J Adamus; N Freemantle; C S Gray; M Lye; D O'Mahony; L Polonski; J Taylor
Journal:  Eur J Heart Fail       Date:  1999-08       Impact factor: 15.534

2.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.

Authors:  L Hansson; L H Lindholm; T Ekbom; B Dahlöf; J Lanke; B Scherstén; P O Wester; T Hedner; U de Faire
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

3.  Atenolol in hypertension: is it a wise choice?

Authors:  Bo Carlberg; Ola Samuelsson; Lars Hjalmar Lindholm
Journal:  Lancet       Date:  2004 Nov 6-12       Impact factor: 79.321

4.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

Authors:  B Pitt; R Segal; F A Martinez; G Meurers; A J Cowley; I Thomas; P C Deedwania; D E Ney; D B Snavely; P I Chang
Journal:  Lancet       Date:  1997-03-15       Impact factor: 79.321

5.  A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.

Authors:  L Køber; C Torp-Pedersen; J E Carlsen; H Bagger; P Eliasen; K Lyngborg; J Videbaek; D S Cole; L Auclert; N C Pauly
Journal:  N Engl J Med       Date:  1995-12-21       Impact factor: 91.245

6.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.

Authors: 
Journal:  Lancet       Date:  1993-10-02       Impact factor: 79.321

7.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

8.  GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1994-05-07       Impact factor: 79.321

9.  ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1995-03-18       Impact factor: 79.321

10.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

Authors:  R Garg; S Yusuf
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

View more
  8 in total

1.  A prescription for better prescribing.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

2.  A prescription for better prescribing.

Authors:  Jeffrey K Aronson; Graeme Henderson; David J Webb; Michael D Rawlins
Journal:  BMJ       Date:  2006-09-02

3.  Balanced prescribing.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2006-12       Impact factor: 4.335

Review 4.  Prescribing for older people.

Authors:  James C Milton; Ian Hill-Smith; Stephen H D Jackson
Journal:  BMJ       Date:  2008-03-15

Review 5.  Chairman of the Joint Formulary Committee, British National Formulary.

Authors:  Martin Kendall
Journal:  Clin Med (Lond)       Date:  2009-08       Impact factor: 2.659

6.  Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.

Authors:  Anthony M Heagerty; Jean-Michel Mallion
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

7.  Using the Causal Inference Framework to Support Individualized Drug Treatment Decisions Based on Observational Healthcare Data.

Authors:  Andreas D Meid; Carmen Ruff; Lucas Wirbka; Felicitas Stoll; Hanna M Seidling; Andreas Groll; Walter E Haefeli
Journal:  Clin Epidemiol       Date:  2020-11-02       Impact factor: 4.790

Review 8.  Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.